Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study

Journal of Patient-Reported Outcomes

Table 3 WPAI:UC scores for the acute phase sample at acute phase visits

		Baseline		Week 3		Week 8			Post hoc comparisons (Bonferroni-adjusted P [α/3])
	N	LS Mean	SE	LS Mean	SE	LS Mean	SD	P	Baseline vs. Week 3	Baseline vs. Week 8	Week 3 vs. Week 8
Absenteeism	367	13.0	1.35	6.6	1.03	4.5	0.80	‡	‡	‡	0.1341
Presenteeism	376	35.9	1.37	21.2	1.15	16.7	1.19	‡	‡	‡	‡
Overall work impairment	365	42.0	1.60	25.4	1.42	19.8	1.39	‡	‡	‡	‡
Activity impairment	579	41.5	1.12	26.2	1.02	19.3	1.02	‡	‡	‡	‡

LS least squares, SE standard error, WPAI:UC Work Productivity and Activity Impairment questionnaire for ulcerative colitis
Findings for each outcome are based on mixed-effects models for repeated measures with subject as a random effect and visit as a fixed effect
Week 8 includes early withdrawal visits during the acute phase
‡P < 0.001